Professor Gail Matthews presenting at CROI 2023. Photo by Roger Pebody.The combination of dolutegravir and darunavir/ritonavir is superior to a boosted protease inhibitor regimen for second-line treatment of people experiencing failure of a first-line regimen containing a non-nucleoside reverse transcriptase inhibitor, Professor Gail Matthews of the University of New South Wales reported at the 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023) in Seattle. The findings come from the D2EFT study, conducted in 14 countries in Africa, Asia and Latin America.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV treatment meets primary endpoint in Phase 3 ARTISTRY-2 trial
-
New data from EACS 2025 on quality of life and comorbidities in people with HIV
-
IDWeek 2025: Real-world findings show lenacapavir effective in highly treatment-experienced people with HIV
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.